Ikarian Capital’s BioXcel Therapeutics BTAI Stock Holding History

Ikarian Capital’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,313	Closed	-$2.48M	–	141
2023 Q1	$2.48M	Sell	8,313 -7,312	-47%	-$3.12M	0.56%	53
2022 Q4	$5.37M	Buy	+15,625	New	+$3.78M	1.3%	26
2022 Q2	–	Sell	-339	Closed	-$113K	–	154
2022 Q1	$113K	Buy	339 +16	+5%	+$4.64K	0.01%	179
2021 Q4	$104K	Buy	+323	New	+$139K	0.02%	168
2021 Q2	–	Sell	-327	Closed	-$226K	–	230
2021 Q1	$226K	Buy	+327	New	+$263K	0.01%	269
2020 Q4	–	Sell	-170	Closed	-$132K	–	238
2020 Q3	$117K	Sell	170 -16,631	-99%	-$12.5M	0.01%	165
2020 Q2	$14.3M	Sell	16,801 -26,556	-61%	-$17.3M	1.13%	24
2020 Q1	$15.5M	Buy	43,357 +33,459	+338%	+$12M	1.17%	21
2019 Q4	$2.31M	Buy	+9,898	New	+$995K	0.37%	60

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ikarian Capital's BTAI Position: Q2 2023 in Review

Ikarian Capital sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 8,313 shares — an estimated $2.48M sold.

Ikarian Capital first reported a position in BTAI in Q4 2019 and held it in 9 quarters. The position peaked at $15.5M in Q1 2020. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

Ikarian Capital reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 8,313 BioXcel Therapeutics shares in Q2 2023, an estimated $2.48M.
Ikarian Capital first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 9 quarters.
Ikarian Capital's BioXcel Therapeutics position peaked at $15.5M in Q1 2020.
88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.